Image courtesy of Shutterstock
The Jenner Institute at Oxford University, together with partners Imaxio and GSK, has started a phase I clinical trial of a novel vaccine candidate aimed at blocking transmission of malaria.
Around half the world’s population is at risk of malaria and the disease led to an estimated 584,000 deaths in 2013. MosquirixTM, a malaria vaccine candidate developed by GSK, has just received a positive scientific opinion from the European Medicines Agency for use in young children. MosquirixTM aims at addressing the objectives set for a first generation vaccine in the WHO malaria vaccine technology roadmap. The roadmap also outlines ambitious goals for second generation vaccines including transmission-blocking vaccines. The latter prevent mosquitoes from transmitting malaria to non-infected persons.